03:29:48 Europe / Stockholm
Svenska | English

Gubra

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-08-23 Kvartalsrapport 2024-Q2
2024-04-04 X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-01 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
Completion of share buy-back programme
2023-09-01 11:41:00

On 28 August 2023, Gubra A/S (“Gubra” or the “Company”) announced resumption of its share buy-back programme of in total 27,271 shares. The purpose of the share buy-back programme is to meet the Company’s obligations arising from its share-based incentive programmes to employees (Restricted Stock Units).
 
Today, Gubra announces the completion of the share buy-back programme. As 1,539 shares were repurchased during the period 30 June to 28 July, the remaining number of shares that have now been repurchased amounts to 25,692 (at a price of approximately DKK 2.8 million).
 
The details for each transaction made under the resumed share buy-back programme is attached to this announcement.
 
With the transactions carried out under the programme, Gubra owns a total of 59,271 own shares, corresponding to 0.4% of the share capital of the Company. The total amount of shares in the company is 16,349,703 including treasury shares.

Contacts at Gubra
Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Attachments
Completion of share buy-back programme
Repurchase Of Shares 28 Aug 2023 10 Oct 2023

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden